体中KDM4D表达升高:巴巴鲁姆多糖的影响和潜在抑制
Juan Gao1,2,3, Yuchuan Wang1,2,3, Ruifang Han1,2,3
1Tianjin Eye Hospital, Tianjin, China.
概括
升高的KDM4D表达驱动质形成. 巴巴多糖 (LBP) 抑制KDM4D,降低pterygium纤维细胞活力,迁移和亡,表明LBP是一种潜在的治疗剂.
科学领域:
- 眼科医生 眼科 眼科
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 是常见的眼睛疾病.
- KDM4D (氨酸脱甲基酶4D) 与细胞增殖和迁移有关.
- 巴巴鲁姆多糖 (LBP) 是一种具有潜在治疗功能的天然化合物.
研究的目的:
- 为了研究KDM4D在pterygium中的作用.
- 探索LBP在pterygium中的治疗潜力.
主要方法:
- 免疫组织化学检测KDM4D在pterygium组织中的表达.
- 基于细胞的测定 (CCK-8,流细胞计,伤愈合) 来评估KDM4D和LBP对膜纤维细胞的影响.
- 定量实时PCR和西白斑用于分析基因和蛋白质表达.
- 液体染色学-质谱学 (LC-MS) 用于差异基因表达分析.
主要成果:
- 与正常结膜相比,KDM4D的表达在质组织中显著更高.
- KDM4D促进了pterygium纤维细胞活力,迁移,并抑制了亡.
- 炎症性细胞因子 (IL-1β,IL-6,IL-8) 提高了KDM4D表达的调节.
- LBP抑制了KDM4D表达,降低了纤维细胞活力,并减弱了KDM4D介导的对迁移和亡的影响.
结论:
- 升高的KDM4D是膜发育的危险因素.
- 通过抑制KDM4D在pterygium纤维细胞中,LBP显示出治疗潜力.
- 低血压可能作为一种新型治疗药物来延缓状的进展.
更多相关视频
11:13Adenoviral Gene Therapy for Diabetic Keratopathy: Effects on Wound Healing and Stem Cell Marker Expression in Human Organ-cultured Corneas and Limbal Epithelial Cells
Published on: April 7, 2016
9.2K
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
414
相关概念视频
02:23Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K